Table 1.
Baseline characteristics and conditions
| Age starting treatment (years), mean ± SD | 46.7 ± 9.68 |
| Male, n (%) | 16 (53.3) |
| Smoker, n (%) | 11(36.7) |
| BMI (kgm-2), mean ± SD | 26.9 ± 5.4 |
| History of IVDU, n (%) | 17 (56.7) |
| Charlson comorbidity index, mean ± SD | 1.9 ± 1.3 |
| Selected comorbidities, n (%) | |
| Diabetes mellitus | 5 (16.7) |
| Diabetes mellitus with complications | 3 (10.0) |
| Chronic kidney disease | 2 (6.7) |
| Chronic hepatitis B | 1 (3.3) |
| Connective tissue disease | 3 (10) |
| COPD | 1 (3.3) |
| Hypertension | 4 (13.3) |
| Psychiatric history (e.g., depression), n (%) | 10 (33.3) |
| Previous CHC treatment (any history), n (%) | 5 (16.7) |
| Previous liver biopsy, n (%) | 3 (10) |
| Fibroscan score (kPA), mean ± SD | 8.5 ± 4.3 |
| Fibro scan score ≥14 kPA, n (%) | 3 (10) |
| Cirrhosis, n (%) | 5 (16.7) |
| Genotype, n (%) | |
| 1 | 17 (56.7) |
| 1a | 9 (30.0) |
| 1b | 7 (23.3) |
| 2 | 1 (3.3) |
| 3 | 10 (33.3) |
| 6 | 2 (6.7) |
| Race, n (%) | |
| Caucasian | 20 (66.7) |
| Asian | 8 (26.7) |
| Other | 2 (6.7) |
| Baseline | |
| Viral load, n (%) | |
| <400 000 (IUmL−1) | 10 (33.3) |
| >400 000 (IUmL−1) | 20 (66.7) |
| AST (UL−1), mean ± SD | 65.4 ± 50.9 |
| ALT (UL−1), mean ± SD | 98.6 ± 85.6 |
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; CHC, chronic hepatitis C; COPD, chronic obstructive pulmonary disease; IVDU, intravenous drug use; SD, standard deviation.